Maximum Dosing for BuFencon Injection (Betamethasone Combination)
For intralesional dermatologic treatment, the maximum recommended dose is 1 mL per week, and for intra-articular or soft tissue injections, dosing should not exceed the FDA-labeled recommendations with careful attention to systemic absorption and cumulative corticosteroid exposure. 1
Weekly Maximum Dosing
Intralesional/Dermatologic Use:
- Maximum of 1 mL per week for intralesional treatment 1
- Administered at 0.2 mL/cm² intradermally using proper technique 1
Intra-articular and Soft Tissue Injections:
- Dosing varies by site and indication, with intervals typically ranging from 3 days to 2 weeks between injections 1
- For bursitis: 1 mL per injection, with repeat injections as needed for recurrent acute episodes 1
- For tenosynovitis/tendinitis: 3-4 local injections at 1-2 week intervals 1
- For foot disorders: 0.25-1 mL per site at intervals of 3 days to 1 week 1
Monthly Maximum Dosing
No specific monthly cumulative maximum is established in the FDA labeling, but several critical considerations apply:
- Systemic absorption occurs with all routes of administration (intra-articular, intralesional, soft tissue), and this must be factored into total corticosteroid burden 1
- Patients receiving concomitant oral or parenteral corticosteroids require dose adjustment accounting for systemic absorption from local injections 1
- High-dose corticosteroid exposure is defined as ≥2 mg/kg/day or ≥20 mg/day prednisone equivalent for ≥2 weeks in relevant clinical contexts 2
Critical Dosing Caveats
Frequency limitations by indication:
- Intralesional dermatologic: Weekly intervals maximum 1
- Tenosynovitis: 1-2 week intervals between injections 1
- Foot disorders: 3 days to 1 week intervals 1
- Intra-articular (large joints): Dosing frequency not explicitly limited but should account for systemic effects 1
Systemic considerations:
- Each mL of BuFencon contains 7 mg total betamethasone (5 mg from dipropionate + 2 mg from sodium phosphate) 1
- Cumulative monthly exposure should be calculated based on injection frequency, volume per injection, and any concurrent systemic corticosteroid therapy
- The dual-acting formulation provides both immediate (sodium phosphate) and sustained (dipropionate) corticosteroid effects, prolonging systemic exposure 1
Avoid exceeding labeled single-dose maximums (1-2 mL depending on joint size for intra-articular use; 1 mL weekly for intralesional use) and maintain appropriate intervals between injections to minimize hypothalamic-pituitary-adrenal axis suppression and other systemic corticosteroid adverse effects 1.